You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
WALTHAM, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020 . The Company will host a conference call and live audio webcast at 8:30 a.m.
Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 development Elacestrant further strengthens Menarini’s global oncology portfolio, recently bolstered by the acquisition of Stemline Therapeutics in the U.S.
Radius partner Teijin Pharma has submitted a New Drug Application for abaloparatide-SC for treatment of osteoporosis in Japan WALTHAM, Mass. , May 27, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that its partner, Teijin Pharma Limited
TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic. Anticipated data read-outs remain on track for second half of 2021 Due to anticipated impact of pandemic, 2020 TYMLOS U.S.
WALTHAM, Mass. , April 28, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors (the “Board”) granted G. Kelly Martin , in connection with his appointment as Chief Executive Officer and President of the Company,
Jesper Hoeiland to step down as President and Chief Executive Officer in order to return to Denmark with his family Jesper will serve as a Senior Advisor to the Company to help facilitate a smooth transition Kelly Martin has been appointed President and Chief Executive Officer WALTHAM, Mass.
WALTHAM, Mass. , April 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Thursday, May 7, 2020 . The Company will host a conference call and live audio webcast at 4:45 p.m.
WALTHAM, Mass. , March 03, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland , President & CEO and Pepe Carmona , CFO will present a corporate update at the Cowen 40 th Annual Healthcare Conference in Boston at 08:40 a.m.
TYMLOS ® U.S. net sales grew to $56 million in the fourth quarter of 2019, totaling $173M for full-year 2019, exceeding the Company’s guidance of $168 to 172M TYMLOS exited 2019 with majority share in new patients 1 , on track for market leadership in 2020 2020 TYMLOS U.S.
WALTHAM, Mass. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona , CFO will present a corporate update at the 9 th Annual SVB Leerink Partners Global Healthcare Conference at 10:30 a.m.
